Researching a molecule that might make prostate cancer cells more susceptible to both chemotherapy and radiotherapy: mTor inhibition to sensitising prostate cancer to irradiation and docetaxel chemotherapy.

Department of Oncology, Imperial College London Hammersmith CampusDr Dmitry Pshezhetskiy£118,8932007 - 2010

Why we funded it

Preliminary data from this project may provide Dr Pshezhetskiy with sufficient information to permit Phase 1 clinical testing of RAD001 in humans. Phase 1 trials are done to find out a treatment's safe dose range, side effects and whether it is effective against the cancer. The potential benefit of this study would be increased local control of prostate cancer treated with radiotherapy, and a survival gain in men treated with chemotherapy for recurrent prostate cancer.

Scientific title

mTor inhibition to sensitising prostate cancer to irradiation and docetaxel chemotherapy.

Research project summary

Dr Pshezhetskiy will explore the potential of a molecule - RAD001 - to make prostate cancer cells more sensitive to chemotherapy and radiotherapy. They have already demonstrated that concentrations of RAD001, which inhibits an enzyme - mTOR kinase - makes prostate cancer cells sensitive to chemo- and radio-therapy. They will further investigate the effects of RAD001 on signaling and study how RAD001 works together with docetaxel chemotherapy and radiation to improve treatment effects.